LivaNova PLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $42.275
- Today's High:
- $42.91
- Open Price:
- $42.55
- 52W Low:
- $40.26
- 52W High:
- $88
- Prev. Close:
- $42.3
- Volume:
- 346013
Company Statistics
- Market Cap.:
- $2.30 billion
- Book Value:
- 22.545
- Revenue TTM:
- $1.02 billion
- Operating Margin TTM:
- 5.55%
- Gross Profit TTM:
- $696.73 million
- Profit Margin:
- -8.44%
- Return on Assets TTM:
- 1.58%
- Return on Equity TTM:
- -6.89%
Company Profile
LivaNova PLC had its IPO on 1993-02-10 under the ticker symbol LIVN.
The company operates in the Healthcare sector and Medical Devices industry. LivaNova PLC has a staff strength of 2,900 employees.
Stock update
Shares of LivaNova PLC opened at $42.55 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $42.28 - $42.91, and closed at $42.71.
This is a +0.97% increase from the previous day's closing price.
A total volume of 346,013 shares were traded at the close of the day’s session.
In the last one week, shares of LivaNova PLC have slipped by -1.73%.
LivaNova PLC's Key Ratios
LivaNova PLC has a market cap of $2.30 billion, indicating a price to book ratio of 2.588 and a price to sales ratio of 2.8203.
In the last 12-months LivaNova PLC’s revenue was $1.02 billion with a gross profit of $696.73 million and an EBITDA of $104.34 million. The EBITDA ratio measures LivaNova PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, LivaNova PLC’s operating margin was 5.55% while its return on assets stood at 1.58% with a return of equity of -6.89%.
In Q4, LivaNova PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1.8%.
LivaNova PLC’s PE and PEG Ratio
- Forward PE
- 24.4499
- Trailing PE
- 0
- PEG
- 5.0239
Its diluted EPS in the last 12-months stands at $-1.59 per share while it has a forward price to earnings multiple of 24.4499 and a PEG multiple of 5.0239. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into LivaNova PLC’s profitability.
LivaNova PLC stock is trading at a EV to sales ratio of 3.2597 and a EV to EBITDA ratio of 190.3233. Its price to sales ratio in the trailing 12-months stood at 2.8203.
LivaNova PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.29 billion
- Total Liabilities
- $297.40 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $9.13 million
- Dividend Payout Ratio
- 0%
LivaNova PLC ended 2023 with $2.29 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.29 billion while shareholder equity stood at $1.21 billion.
LivaNova PLC ended 2023 with $0 in deferred long-term liabilities, $297.40 million in other current liabilities, 82424000.00 in common stock, $-984030000.00 in retained earnings and $768.79 million in goodwill. Its cash balance stood at $214.17 million and cash and short-term investments were $214.17 million. The company’s total short-term debt was $32,813,000 while long-term debt stood at $518.07 million.
LivaNova PLC’s total current assets stands at $886.14 million while long-term investments were $16.27 million and short-term investments were $0. Its net receivables were $183.11 million compared to accounts payable of $74.31 million and inventory worth $129.38 million.
In 2023, LivaNova PLC's operating cash flow was $0 while its capital expenditure stood at $9.13 million.
Comparatively, LivaNova PLC paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $42.71
- 52-Week High
- $88
- 52-Week Low
- $40.26
- Analyst Target Price
- $69
LivaNova PLC stock is currently trading at $42.71 per share. It touched a 52-week high of $88 and a 52-week low of $88. Analysts tracking the stock have a 12-month average target price of $69.
Its 50-day moving average was $49.49 and 200-day moving average was $54.26 The short ratio stood at 2.85 indicating a short percent outstanding of 0%.
Around 39.9% of the company’s stock are held by insiders while 10745.7% are held by institutions.
Frequently Asked Questions About LivaNova PLC
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.